The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis
Open accessAbstract
Chronic hepatitis B viral (HBV) infection remains a significant global health problem. Evidence‐based guidelines are needed to help providers determine when treatment should be initiated, which medication is most appropriate, and when treatment can safely be stopped. The American Association for the Study of Liver Diseases HBV guideline methodology and writing committees developed a protocol a priori for this systematic review. We searched multiple databases for randomized controlled trials and controlled observational studies that enrolled adults ≥18 years old diagnosed with chronic HBV infection who received antiviral therapy. Data extraction was done by pairs of independent reviewers. We included 73 studies, of which 59 (15 randomized controlled trials and 44 observational studies) reported clinical outcomes. Moderate‐quality evidence supported the effectiveness of antiviral therapy in patients with immune active chronic HBV infection in reducing the risk of cirrhosis, decompensated liver disease, and hepatocellular carcinoma. In immune tolerant patients, moderate‐quality evidence supports improved intermediate outcomes with antiviral therapy. Only very low‐quality evidence informed the questions about discontinuing versus continuing antiviral therapy in hepatitis B e antigen‐positive patients who seroconverted from hepatitis B e antigen to hepatitis B e antibody and about the safety of entecavir versus tenofovir. Noncomparative and indirect evidence was available for questions about stopping versus continuing antiviral therapy in hepatitis B e antigen‐negative patients, monotherapy versus adding a second agent in patients with persistent viremia during treatment, and the effectiveness of antivirals in compensated cirrhosis with low‐level viremia. Conclusion: Most of the current literature focuses on the immune active phases of chronic HBV infection; decision‐making in other commonly encountered and challenging clinical settings depends on indirect evidence. (H epatology 2016;63:284–306)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Self-citationChronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Self-citationLamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
AASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
Self-citationOtt, J. J., Stevens, G. A., Groeger, J., & Wiersma, S. T. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.12.116 · Cited by 1,843
Panahi, M., Naderi, M., Morteza, T. S., & Parizadeh, S. M. J. (2007) · Cited by 1,722
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
Iloeje, U. H., Yang, H., Su, J., Jen, C., You, S., & Chen, C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.016 · Cited by 1,528
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
Lau, G. K. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043470 · Cited by 1,519
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051285 · Cited by 1,444
Self-citationLamivudine as Initial Treatment for Chronic Hepatitis B in the United States
Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H.-W. L., Goodman, Z., Crowther, L., Condreay, L. D., Woessner, M., Rubin, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411702 · Cited by 1,226
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Lai, C.-L., Shouval, D., Lok, A. S., Chang, T.-T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R. C., Cross, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051287 · Cited by 1,188
Self-citationMarcellin, P., Lau, G. K. K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., Lu, Z.-M., Piratvisuth, T., Germanidis, G., Yurdaydin, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040431 · Cited by 1,145
Mast, E. E., Weinbaum, C. M., Fiore, A. E., Alter, M. J., Bell, B. P., Finelli, L., Rodewald, L. E., Douglas, J. M., Janssen, R. S., & Ward, J. W. (2006) · PubMed · Cited by 1,132
LAMIVUDINE AS INITIAL TREATMENT FOR CHRONIC HEPATITIS B IN THE UNITED STATES
Ules, J., Ienstag, L. D., Chiff, E. U. R. S., Right, L. W., Errillo, R. O. P. P., Ann, L. H., Rowther, L. Y. C., Ondreay, D. C., Oessner, M. A. W., Ubin, M. A. R., et al. (1999) · Cited by 1,116
Weinbaum, C. M., Mast, E. E., & Ward, J. W. (2009) · Hepatology · doi:10.1002/hep.22882 · Cited by 815
Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B
Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C. M., Mohr, L., & Häussinger, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342202 · Cited by 803
Long-term safety of lamivudine treatment in patients with chronic hepatitis B
Lok, A. S. F., Lai, C.-L., Leung, N., Yao, G.-B., Cui, Z.-Y., Schiff, E. R., Dienstag, J. L., Heathcote, E. J., Little, N. R., Griffiths, D. A., et al. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.033 · Cited by 764
Self-citationHosaka, T., Suzuki, F., Kobayashi, M., Seko, Y., Kawamura, Y., Sezaki, H., Akuta, N., Suzuki, Y., Saitoh, S., Arase, Y., et al. (2013) · Hepatology · doi:10.1002/hep.26180 · Cited by 710
Wong, G. L.-H., Chan, H. L.-Y., Mak, C. W.-H., Lee, S. K.-Y., Ip, Z. M.-Y., Lam, A. T.-H., Iu, H. W.-H., Leung, J. M.-S., Lai, J. W.-Y., Lo, A. O.-S., et al. (2013) · Hepatology · doi:10.1002/hep.26301 · Cited by 488
Murad, M. H., Montori, V. M., Ioannidis, J. P. A., Jaeschke, R., Devereaux, P. J., Prasad, K., Neumann, I., Carrasco-Labra, A., Agoritsas, T., Hatala, R., et al. (2014) · JAMA · doi:10.1001/jama.2014.5559 · Cited by 454
Self-citationKowdley, K. V., Wang, C. C., Welch, S., Roberts, H., & Brosgart, C. L. (2012) · Hepatology · doi:10.1002/hep.24804 · Cited by 400
The Prevalence of Hepatitis B Virus Infection in the United States in the Era of Vaccination
Wasley, A., Kruszon‐Moran, D., Kuhnert, W., Simard, E. P., Finelli, L., McQuillan, G., & Bell, B. (2010) · The Journal of Infectious Diseases · doi:10.1086/653622 · Cited by 351
Brunetto, M. R., Oliveri, F., Coco, B., Leandro, G., Colombatto, P., Gorin, J. M., & Bonino, F. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00266-5 · Cited by 331
Wu, C.-Y., Lin, J.-T., Ho, H. J., Su, C.-W., Lee, T.-Y., Wang, S.-Y., Wu, C., & Wu, J.-C. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.03.048 · Cited by 319
Liaw, Y.-F., Sheen, I.-S., Lee, C.-M., Akarca, U. S., Papatheodoridis, G. V., Wong, F. S.-H., Chang, T.-T., Horban, A., Wang, C., Kwan, P., et al. (2011) · Hepatology · doi:10.1002/hep.23952 · Cited by 316
Garg, H., Sarin, S. K., Kumar, M., Garg, V., Sharma, B. C., & Kumar, A. (2011) · Hepatology · doi:10.1002/hep.24109 · Cited by 264
Yuen, M.-F., Seto, W.-K., Chow, D. H.-F., Tsui, K., Wong, D. K.-H., Ngai, V. W.-S., Wong, B. C.-Y., Fung, J., Yuen, J. C.-H., & Lai, C.-L. (2007) · Antiviral Therapy · doi:10.1177/135965350701200816 · Cited by 257
Papatheodoridis, G. V., Manesis, E., & Hadziyannis, S. J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00094-5 · Cited by 246
Liaw, Y., Raptopoulou‐Gigi, M., Cheinquer, H., Sarin, S. K., Tanwandee, T., Leung, N. W. Y., Peng, C., Myers, R. P., Brown, R. S., Jeffers, L. J., et al. (2011) · Hepatology · doi:10.1002/hep.24361 · Cited by 232
Self-citation&NA; (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200104000-00030 · Cited by 232
Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection
Iloeje, U. H., Yang, H., Jen, C., Su, J., Wang, L., You, S., & Chen, C. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.06.015 · Cited by 230
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07236-5 · Cited by 230
Fattovich, G., Giustina, G., Realdi, G., Corrocher, R., & Schalm, S. W. (1997) · Hepatology · doi:10.1002/hep.510260536 · Cited by 229
Benvegnù, L. (1998) · Padua Research Archive (University of Padova) · Cited by 221
MATSUMOTO, A., TANAKA, E., ROKUHARA, A., KIYOSAWA, K., KUMADA, H., OMATA, M., OKITA, K., HAYASHI, N., OKANOUE, T., & IINO, S. (2005) · Hepatology Research · doi:10.1016/j.hepres.2005.02.006 · Cited by 194
Ikeda, K., Saitoh, S., Suzuki, Y., Kobayashi, M., Tsubota, A., Fukuda, M., Koida, I., Arase, Y., Chayama, K., Murashima, N., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980301)82:5<827::aid-cncr5>3.0.co;2-g · Cited by 175
Chan, H. L. Y., Chan, C. K., Hui, A. J., Chan, S., Poordad, F., Chang, T.-T., Mathurin, P., Flaherty, J. F., Lin, L., Corsa, A., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.044 · Cited by 172
Lim, Y., Han, S., Heo, N., Shim, J. H., Lee, H. C., & Suh, D. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.033 · Cited by 147
Gordon, S. C., Lamerato, L. E., Rupp, L. B., Li, J., Holmberg, S. D., Moorman, A. C., Spradling, P. R., Teshale, E. H., Vijayadeva, V., Boscarino, J. A., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.09.062 · Cited by 143
Kumada, T., Toyoda, H., Tada, T., Kiriyama, S., Tanikawa, M., Hisanaga, Y., Kanamori, A., Niinomi, T., Yasuda, S., Andou, Y., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.025 · Cited by 142
Sinn, D. H., Lee, J., Goo, J., Kim, K., Gwak, G., Paik, Y., Choi, M. S., Lee, J. H., Koh, K. C., Yoo, B. C., et al. (2015) · Hepatology · doi:10.1002/hep.27889 · Cited by 131
Eun, J. R., Lee, H. J., Kim, T. N., & Lee, K. S. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.02.026 · Cited by 122
Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B
Wong, V. W., Wong, G. L., Yiu, K. K., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.043 · Cited by 115
Chan, H. L., Chen, Y. C., Gane, E. J., Sarin, S. K., Suh, D. J., Piratvisuth, T., Prabhakar, B., Hwang, S. G., Choudhuri, G., Safadi, R., et al. (2012) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2012.01600.x · Cited by 91
Gish, R. G., Clark, M. D., Kane, S. D., Shaw, R. E., Mangahas, M., & Baqai, S. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.04.008 · Cited by 88
Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B
Mauss, S., Berger, F., Filmann, N., Hueppe, D., Henke, J., Hegener, P., Athmann, C., Schmutz, G., & Herrmann, E. M. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.030 · Cited by 86
Chan, H. L., Wang, H., Niu, J., Chim, A. M., & Sung, J. J. �. (2007) · Antiviral Therapy · doi:10.1177/135965350701200308 · Cited by 85
Sun, L., Yu, J., Zhao, Y., Kang, P., & Li, S. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06089.x · Cited by 82
Fung, J., Lai, C., Tanaka, Y., Mizokami, M., Yuen, J., Wong, D. K.-H., & Yuen, M. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.200 · Cited by 82
Cui, Y., Fang, Y., Wang, Y.-B., Song, X.-Q., Liu, L., Lei, X.-Z., Zheng, M., Tang, H., & Feng, P. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1257-7 · Cited by 81
Chan, H. L., Tsang, S. W., Hui, Y., Leung, N. W. Y., Chan, F. K. L., & Sung, J. J. �. (2002) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2002.00385.x · Cited by 75
Chaung, K. T., Ha, N. B., Trinh, H. N., Garcia, R. T., Nguyen, H. A., Nguyễn, K., García, G., Ahmed, A., Keeffe, E. B., & Nguyen, M. H. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31825ceed9 · Cited by 73
Self-citationMahmood, S., Niiyama, G., Kamei, A., Izumi, A., Nakata, K., Ikeda, H., Suehiro, M., Kawanaka, M., Togawa, K., & Yamada, G. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01077.x · Cited by 54
Chen, C., Lin, C., Hu, T., Hung, C., Tseng, P., Wang, J., Chang, J.-Y., Lu, S., Chien, R., & Lee, C. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.013 · Cited by 52
Tien, C., Xu, J. J., Chan, L. S., Chang, M., Lim, C., Lee, S., Huh, B., Shinada, S., Bae, H., & Fong, T. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3363-4 · Cited by 46
Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis
Das, K., Das, K., Datta, S., Pal, S., Hembram, J. R., Dhali, G. K., Santra, A. K., & Chowdhury, A. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02255.x · Cited by 45
Batırel, A. A., Güçlü, E., Arslan, F., Kocak, F., Karabay, O., Ozer, S., Turanlı, M., & Mert, A. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.09.004 · Cited by 42
Mallet, V. O., Schwarzinger, M., Vallet‐Pichard, A., Fontaine, H., Corouge, M., Sogni, P., & Pol, S. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.11.021 · Cited by 40
Zhang, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i16.4745 · Cited by 32
Kim, C. H., Um, S. H., Seo, Y. S., Jung, J. Y., Kim, J.-D., Yim, H. J., Keum, B., Kim, Y. S., Jeen, Y. T., Lee, H. S., et al. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07167.x · Cited by 30
The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis.
Cholongitas, Ε., Papatheodoridis, G., Goulis, J., Vlachogiannakos, J., Karatapanis, S., Ketikoglou, J., Vasiliadis, T., Kontos, G., Karlaftis, A., & Akriviadis, E. A. (2015) · PubMed Central · Cited by 27
Short-term entecavir therapy of chronic severe hepatitis B.
Chen, J., Han, J., Liu, C., Yu, R., Li, F.-Z., Li, Q., & Gong, G. (2009) · PubMed · Cited by 26
Lin, B., Pan, C. Q., Xie, D., Xie, J., Xie, S.-B., Zhang, X., Wu, B., Lin, C., & Gao, Z. (2013) · Hepatology International · doi:10.1007/s12072-012-9415-y · Cited by 25
Early Entecavir Treatment for Chronic Hepatitis B with Severe Acute Exacerbation
Tsai, W., Chiang, P., Chan, H., Lin, H., Lai, K., Cheng, J., Chen, W.-C., Tsay, F., Wang, H.-M., Tsai, T., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02400-13 · Cited by 17
Cited by
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Self-citationAASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2016) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,006
Self-citationSingal, A. G., Kanwal, F., & Llovet, J. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00825-3 · Cited by 951
Schillie, S., Vellozzi, C., Reingold, A., Harris, A., Haber, P., Ward, J. W., & Nelson, N. P. (2018) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6701a1 · Cited by 815
Global burden of hepatitis B virus: current status, missed opportunities and a call for action
Hsu, Y.-C., Huang, D. Q., & Nguyen, M. H. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00760-9 · Cited by 632
Metadata
- Authors
- Lok, A. S. F., McMahon, B. J., Brown, R. S., Wong, J. B., Ahmed, A. T., Farah, W., Almasri, J., Alahdab, F., Benkhadra, K., Mouchli, M. A., Singh, S., Mohamed, E. A., Abu Dabrh, A. M., Prokop, L. J., Wang, Z., Murad, M. H., & Mohammed, K.
- Venue
- Hepatology
- Published
- 2015-11-13
- Volume
- 63
- Issue
- 1
- Pages
- 284-306
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2173855355
- Cited by
- 552
- References
- 69
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.